(Use several sheets if necessary)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

				U.i	S. PATENTS	
Examiner Initial*	Cite No.	Patent Number	Kind Code	Issue Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
	1.	2928833		1960-03-15	Leake et al	
	2.	4005208		1977-01-25	Bender	
	3.	4599338		1986-07-08	Regnier et al.	This patent appears to be an English language equivalent toEP0149578 cited herein.
	4.	5051517		1991-09-24	Findeisen	This patent appears to be an English language equivalent toEP0399285 cited herein.
	5.	5223499	A	1993-06-29	Greenlee	
	6.	5234897	I <sub>A</sub>	1993-08-10	Findeisen et al.	
	7.	5266555	A	1993-11-30	Findeisen et al.	This patent appears to be an English language equivalent toEP0524482 cited herein.
	8.	5389642	A	1995-02-14	Dorsch	
	9.	5470579	A	1995-11-28	Bonte et al.	This patent appears to be an English language equivalent toWO9107945 cited herein.
	10.	5719279	A	1998-02-17	Kuefner-Muhl et al.	This patent appears to be an English language equivalent toWO94/03456 cited herein.
	11.	5753635	A	1998-05-19	Buckman	
	12.	6303661	B1	2001-10-16	Demuth	
	13.	6342601	B1	2002-01-29	Bantick	
	14.	6548481	B1	2003-04-15	Demuth et al.	
	15.	6821978	B2	2004-11-23	Chackalamannil	
	16.	6869947	B2	2005-03-22	Kanstrup	
	17.	7060722	B2	2006-06-13	Kitajima	
	18.	7074794	B2	2006-07-11	Kitajima	This patent appears to be an English language equivalent toWO2002/14271 cited herein.
	19.	7074798	B2	2006-07-11	Yoshikawa	
	20.	7074923	B2	2006-07-11	Dahanukar	
	21.	7109192	B2	2006-09-19	Hauel	
	22.	7179809	B2	2007-02-20	Eckhardt	
	23.	7183280	B2	2007-02-27	Himmelsbach	
	24.	7192952	B2	2007-03-20	Kanstrup	
	25.	7217711	B2	2007-05-15	Eckhardt	·
	26.	7235538	B2	2007-06-26	Kanstrup et al.	

	U.S. PATENT APPLICATION PUBLICATIONS					
Examiner Initial*				Publication Date Name of Patentee or Applicant		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
	1.	11/744700		2007-05-04	Sieger	
	1 2	11/744701		2007 OF 04	Kohleauach	

Examiner:	/Mark Berch/ (04/03/2008)	Date Considered:
-----------	---------------------------	------------------

<sup>\*</sup>Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICATION

(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

App	olication Number:	10/634,047
Fili	ng Date:	August 4, 2003
Firs	t Named Inventor:	Roland MAIER
Art	Unit:	1624
Exa	miner Name:	Mark L. BERCH
Atto	orney Docket Number:	01-1385

Examiner	Cite	Publication	Kind	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines where Relevant
Initial*				of Cited Document	Passages or Relevant Figures Appear of Relevant Comments	
	3.	2002/0161001	A1	2002-10-31	Kanstrup	
	4.	2002/0169174	A1	2002-11-14	Chackalamannil et al.	
	5.	2002/0198205	A1	2002-12-26	Himmelsbach	This document appears to be an apparent English language equivalent to WO2002068420 cited herein.
	6.	2003/0199528	A1	2003-10-23	Kanstrup	
	7.	2003/0232987	A1	2003-12-18	Dahanukar et al.	
	8.	2003/0236272	A1	2003-12-25	Carr	
	9.	2003/0105077	A1	2003-06-05	Kanstrup, A.B. et al.	
	10.	2004/0034014	A1	2004-02-19	Kanstrup, A.B. et al.	
	11.	2004/0077645	A1	2004-04-22	Himmelsbach et al.	This document appears to be an apparent English language equivalent to WO2002068420 cited herein.
	12.	2004/0082570	A1	2004-04-29	Yoshikawa	
	13.	2004/0087587	A1	2004-05-06	Himmelsbach	
	14. 2004/0097510 A1 2004-05-20		2004-05-20	Himmelsbach et al.		
	15.	2004/0122228	A1	2004-06-24	Maier	
	16.	2004/0138214	4/0138214 A1 2004-07-15		Himmelsbach et al.	
	17.	2004/0138215	A1	2004-07-15	Eckhardt	This document appears to be an apparent English language equivalent to WO2004/046148 cited herein.
	18.	2004/0166125	A1	2004-08-26	Himmelsbach	
		2005/0020574	A1	2005-01-27	Hauel, N. et al.	
	20.	2005/0026921	A1	2005-02-03	Eckhardt	
	21.	2005/0130985	A1	2005-06-16	Himmelsbach	
	22.		A1	2005-08-04	Eckhardt et al.	
	23.	2005/0187227	A1	2005-08-25	Himmelsbach et al.	
	24.	2005/0203095	A1	2005-09-15	Eckhardt	
	25.	2005/0234108	A1	2005-10-20	Himmelsbach et al.	
	26.	2005/0261352	A1	2005-11-24	Eckhardt	
	27.	2006/0004074	A1	2006-01-05	Eckhardt	
	28.	2006/0058323	A1	2006-03-16	Eckhardt et al.	
	29.	2006/0063787	A1	2006-03-23	Yoshikawa	
	30.	2006/0079541	A1	2006-04-13	Langkopf	This document appears to be an apparent English language equivalent to WO2006/029769 cited herein.
	_31.	2006/0142310	A1	2006-06-29	Pfrengle et al.	This document appears to be an apparent English language equivalent to WO2006/048427 cited herein.
	32.	2006/0173056	A1	2006-08-03	Kitajima	
	33.	2006/0205711	A1	2006-09-14	Himmelsbach	This document appears to be an apparent English language equivalent to DE10117803 cited herein.

Examiner:	/Mark Berch/ (04/03/2008)	Date Considered:
-----------	---------------------------	------------------

<sup>\*</sup>Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

	U.S. PATENT APPLICATION PUBLICATIONS								
Examiner Cite Publication Initial* No. Number				Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments				
	34.	2006/0247226	A1	2006-11-02	Himmelsbach				
	35.	2007/0027168	A1	2007-02-01	Pfrengle et al.				
	36.	2007/0088038	A1	2007-04-19	Eckhardt				
	37.	2007/0093659	A1	2007-04-26	Bonfanti				
	38.	2007/0142383	A1	2007-06-21	Eckhardt				
	39.	2007/0281940	A1	2007-12-06	Dugi				

FOREIGN PATENT DOCUMENTS								
Examiner		Foreign Document	Country	Kind	Publication	Name of Patentee or Applicant of	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant	√1
Initial*	No.	Number	Code	Code	Date	cited Document	Comments	V.
	1.	2136288	CA	A1	1995-05-24	Merck Patent GmbH	This document appears to be an apparent English language equivalent to EP0657454 cited herein	
	2.	2418656	CA	A1	2002-02-21	Mitsubishi Pharma Corporation		
	3.	2496249	CA	A1	2004-04-03	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004018468 cited herein	
	4.	2496325	CA	A1	2004-03-04	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO20040184687 cited herein	
	5.	2505389	CA	A1	2004-05-21	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004041820 cited herein	
	6.	2508233	CA	A1	2004-06-17	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004050658 cited herein	
	7.	2529729	CA	A1	2004-12-23	BI International GmbH	This document appears to be an apparent English language equivalent to WO2004111051 cited herein	
	8.	2543074	CA	A1	2005-06-30	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/058901 cited herein	
	9.	2555050	CA	A1	2005-09-15	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/085246 cited herein	
	10.	2556064	CA	A1	2005-09-09	Bl International GmbH	This document appears to be an apparent English language equivalent to WO2005/082906 cited herein	
	11.	2590912	CA	A1	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	This document appears to be an English language equivalent to WO2006068163 cited herein	

 $<sup>^{1}</sup>$   $\,\,\sqrt{}$  indicates English Language translation is attached

Examiner:

/Mark Berch/ (04/03/2008)

Dawning:		Date Commerces
*Examiner: Initial if citation considered,	whether or not cita	ation is in conformance with MPEP Section 609; Draw line through
citation if not in conformance and not cons-	idered. Include ce	ppy of this form with next communication to applicant.

Date Considered

(Use several sheets if necessary)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

			FOREIG	N PATENTI	OCUMENTS		
12.	10109021	DE	A1	2002-09-05	Boehringer Ingelheim Pharma KG	US2006/0205711 cited herein appears to be an apparent English language equivalent	
13.	10117803	DE	A1	2002-10-24	Boehringer Ingelheim Pharma KG		
14.	0149578		A2	1985-07-24		US4599338 cited herein appears to be an apparent English language equivalent	
						US5051517 cited herein appears to be an apparent English language	
15.	0399285	EP	A1	1990-11-28	Bayer AG	equivalent	
16.	0400974	EP	A2	1990-05-12	Merck & Co. Inc.		
17.	0412358	EP	A1	1991-02-13	Baver AG		V
18.	0524482	EP	A1	1993-01-27		US5266555 cited herein appears to be an apparent English language equivalent	
19.	0657454	FP	A1	1995-06-14	Merck Patent GmbH	CA2136288 cited herein appears to be an apparent English language equivalent	
20.	1338595		A2	2003-08-27		- Garage	t
21.	1514552		A1		Eisai Co. Ltd		T
22.	1537880		A1		Takeda Pharmaceutical Company Limited		
23.	385302	ES	A1	1973-04-16	Laboratorios Miquel		l٧
24.	2707641	FR	A1	1995-01-20	Fournier Ind. Et Sante		
25.	2003/300977	JP		2003-10-21	Sumitomo Pharma Co. Ltd		V
26.	2006/045156	JP		2006-02-16	Sumitomo Pharma		V
27.	S37-4895	JP		1962-06-16	Yoshitomi Pharmaceutical Corp.		V
28.	91/07945	wo	A1	1991-06-13	LVMH Recherche	US5470579 cited herein appears to be an apparent English language equivalent	
29.	94/03456	wo	A1	1994-02-17	Boehringer Ingelheim Int'l GmbH	US5719279 cited herein appears to be an apparent English language equivalent	
30.	99/29695		A1		Astra Aktiebolag		L
31.	2002/02560	wo	A2	2002-01-10	Novo Nordisk A/S		L
32.	2002/068420	wo	A1	2002-09-06	Boehringer Ingelheim Pharma KG	US2002/198205 cited herein appears to be an apparent English language equivalent	
33.	2002/14271	wo	A1	2002-02-21	Welfide Corporation	US7074794 cited herein appears to be an apparent English language equivalent	
34.	2002/24698		A1		Schering Corporation		Γ
35.	2003/004496	wo	A1	2003-01-16	Novo Nordisk A/S		
36.	2003/024965	wo	A2	2003-03-27	Novo Nordisk A/S		L
37.	2003/057200	wo	A2	2003-07-17	Novo Nordisk A/S		Γ
38.	2003/104229	wo	A1	2003-12-18	Eisai Co., Ltd.	US2004116328 cited herein appears to be an apparent English language equivalent	

Examiner:	/Mark Berch/ (04/03/2008)	Date Considered:

<sup>\*</sup>Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

 			_FOREIG	N PATENT I	OCUMENTS		
- 1					Boehringer Ingelheim	CA2496325 cited herein appears to be	
20						an apparent English language	
39.	2004/018467	wo	A2	2004-03-04		equivalent	_
- 1					Boehringer Ingelheim	CA2496249 cited herein appears to be	
					Pharma GmbH & Co.	an apparent English language	
40.	2004/018468		A2	2004-03-04		equivalent	↓_
41.	2004/033455	wo	A2	2004-04-22	Novo Nordisk		ı
						CA2505389 cited herein appears to be	Г
					Boehringer Ingelheim	an apparent English language	ı
42.	2004/041820	wo	A1	2004-05-21	Pharma GmbH	equivalent	┖
					Boehringer Ingelheim	US2004/0138215 cited herein appears	Г
					Pharma GmbH & Co.	to be an apparent English language	
43.	2004/046148	wo	A1	2004-06-03		equivalent	
					Sumitomo Pharm		V
44.	2004/048379	WO	A1	2004-06-10			N
- 1					Boehringer Ingelheim	CA2508233 cited herein appears to be	
					Pharma GmbH & Co.	an apparent English language	ı
45.	2004/050658	WO	A1	2005-06-17		equivalent	L
					Fujisawa Pharma.		
46.	2004/108730	WO	A1	2004-12-16	Co., Ltd.		
						CA2529729 cited herein appears to be	
						an apparent English language	ı
47.	2004/111051	WO	A1	2005-12-23	BI Int'l GmbH	equivalent	L
- 1						CA2543074 cited herein appears to be	
						an apparent English language	ı
48.	2005/058901	WO	A1	2005-06-30	BI Int'l GmbH	equivalent	L
- 1						CA2556064 cited herein appears to be	ı
						an apparent English language	ı
49.	2005/082906	WO	A1	2005-09-09	BI Int'l GmbH	equivalent	L
- 1				1		CA2555050 cited herein appears to be	
		l	1.	1		an apparent English language	
50.	2005/085246	WO	A1	2005-09-15	BI Int'l GmbH	equivalent	L
						US2006079541 cited herein appears	
					BI Pharma GmbH &	to be an apparent English language	
51.	2006/029769	WO	A1	2006-03-23	Co. KG	equivalent	L
						US2006142310 cited herein appears	Γ
						to be an apparent English language	
52.	2006/048427	WO	A1	2006-05-11	BI Int'l GmbH	equivalent	L
					Dainippon Sumitomo	CA2590912 cited herein appears to be	
53.	2006/068163	WO .	A1	2006-06-29	Pharma Co., Ltd.	an English language equivalent	
					F. Hoffmann-La		Γ
54.	2007/017423	lwo	A2	2007-02-15	Roche AG	1	1

NON-PATENT LITERATURE DOCUMENTS						
Examiner Initial*	No					
	1.	BELJEAN-LEYMARIE et al., Hydrazines et hydrazones hétérocycliques. IV. Synthèses de dérivés de l'hydrazine dans la série des imidazo[4,5-d]pyridazinones-4, Can. J. Chem., Vol. 61, No. 11, 1983, pp. 2563-2566.	√			
	2.	BOLLAG, R.J. ET AL; "Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors," Endocrinology, Vol. 141, No. 3, 2000, pp. 1228-1235.				

<sup>&</sup>lt;sup>2</sup> √ indicates English Language translation is attached

Mark Barob/ (04/02/2008)

Examiner:	Main Belefit (04/00/2000)	Date Considered:	l
*Examiner:	Initial if citation considered, whether or not ci	itation is in conformance with MPEP Section 609; Draw line through	
citation if no	at in conformance and not considered. Include a	conv of this form with next communication to applicant	l

(Use several sheets if necessary)

Application Number:	10/634,047
Filing Date:	August 4, 2003
First Named Inventor:	Roland MAIER
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1385

3,	BRITTAIN, H.G., "Methods for the Characterization of Polymorphs: X-Ray Powder Diffraction," Polymorphism in Pharmaceutical Solids, 1999, p. 235-238	
3.	CAIRA, M.R., "Crystalline polymorphism of organic compounds" Topics in Current Chemistry, Springer, Berlin, Vol. 198,	-
4.	1998, p. 163-208	
	CONARELLO, S.L. ET AL; "Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance,"	-
	PNAS 2003; 100:6825-6830; originally published online May 14, 2003; information current as of December 2006.	
5.	www.pnas.org/cgi/content/full/100/11/6825.	
	DEACON, C.F. ET AL; "Dipeptidyl peptidase IV inhabitation as an approach to the treatment and prevention of type 2	
6.	diabetes: a historical perspective;" Biochemical and Biophysical Research Communications (BBRC) 294 (2002) 1-4.	
_	DeMEESTER, I. ET AL.; "CD26, let it cut or cut it down", Review: Immunology Today; August 1999, Vol. 20, No. 8	
7.	pp.367-375	
	KOROM, S. ET AL; "Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat	
8.	recipients 12, Transplantation, May 27, 1997, Vol. 63, no 10, pp 1495-1500.	
	POSPISILIK, ET AL; "Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β -Cell Survival and Islet Neogenesis in	
9.	Streptozotocin-Induced Diabetic Rats; Diabetes, Vol. 52, March 2003 pp 741-750.	_
10	RHEE ET AL.: "Nitrogen-15-Labeled Deoxynucleosides. 3. Synthesis of [3-15N]-2'-Deoxyadenosine" J. Am. Chem. Soc.	
10.	1990, 112, 8174-8175	_
11	SEDO, A. ET AL; "Dipeptidyl peptidase IV activity and/or structure homologs: Contributing factors in the pathogenesis of	
11.	rheumatoid arthritis?" Arthritis Research & Therapy 2005, Vol. 7, pp. 253-269  TANAKA, S., ET AL: "Suppression of Arthritis by the Inhibitors of Dipeptidyl Peptidase IV." In. J. Immunopharmac., Vol.	_
12	19, No. 1, pp. 15-24, 1997	
12.	WOLFF, M.E.; "Burger's Medicinal Chemistry and Drug Discovery" Fifth Edition, Vol 1: Principles and Practice, pgs. 975-	-
13	977, 1994, John Wiley & Sons, Inc.,	
13	ZHONG, QING ET AL; "Glucose-dependent insulinotropic peptide stimulates proliferation and TGF-B release from MG-	-
14	63 cells," Peptides 24 (2003) 611-616	
	Chemical Abstracts Accession No. 1987:95577: Abstract of ROMANENKO et al., "Synthesis and biological activity of 3-	$\neg$
	methyl, 7- or 8-alkyl, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Farmatsevtichnii Zhurnal, 1986, (Kiev),	
15.	Vol. 5, 1986, pp. 41-44.	
	Chemical Abstracts Accession No. 106:95577 ROMANENKO ET AL "Synthesis and biological activity of 3-methyl, 7-or	$\neg$
16.	8-alkyl-7.8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Zaporozh, Med. Institute (1986)	
	YOSHIKAWA, SEIJI ET AL.: Chemical Abstract of Japanese Patent No. WO 2003/104229 "Preparation of purinone	
17.	derivatives as dipeptidylpeptidase IV (DPP-IV) inhibitors	
18	International Search Report for PCT/EP03/09127 mailed November 28, 2003.	$\neg$
1		$\dashv$
19.	International Search Report for PC (PEPOS) 12021 mailed watch 30, 2004.	_
20.	International Search Report for PCT/EP03/13648 mailed April 5, 2004.	
21.	International Search Report for PCT/EP2007/054270 mailed August 14, 2007.	
22.	* '	
		-
23.	International Search Report for PCT/EP2007/054204 mailed August 3, 2007.	
24.	International Search Report for PCT/EP2007/054201 mailed August 29, 2007	

Examiner:	/Mark Berch/ (04/03/2008)	Date Considered:
ware .	T 30 1 10 3 20 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	